Hide metadata

dc.date.accessioned2018-05-24T09:51:21Z
dc.date.available2018-05-24T09:51:21Z
dc.date.created2018-02-07T13:16:12Z
dc.date.issued2018
dc.identifier.citationKramer, Anneke Pippias, Maria Noordzij, Marlies Stel, VS Afentakis, Nikolaos Ambühl, Patrice M Andrusev, AM Fuster, EA Monzon, Federico E Åsberg, Anders Barbullushi, M Bonthius, Marjolein Caskey, Fergus J De La Nuez, Pablo Castro Cernevskis, Harijs des Grottes, Jean-Marin Garneata, Liliana Golan, Eliezer Hemmelder, Marc H. Ioannou, Kyriakos Jarraya, Facial Kolesnyk, Mykola Komissarov, Kirill Lassalle, Mathilde Macário, Fernando Mahillo-Duran, Beatriz de Francisco, A Pálsson, Runólfur Pechter, Ülle Resic, Halima Rutkowski, Boleslaw De Pablos, Carmen Santiuste Seyahi, Nurhan Ogrizovic, Sanja Simic Roblero, María Fernanda Slon Spustová, Viera Stojceva-Taneva, Olivera Traynor, Jamie P. Massy, Ziad A. Jager, Kitty J . The European Renal Association - European Dialysis and Transplantation Association (ERA-EDTA) registry Annual Report 2015: a summary. Clinical Kidney Journal. 2018, 11(1), 108-122
dc.identifier.urihttp://hdl.handle.net/10852/61718
dc.description.abstractBackground: This article summarizes the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry’s 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2015 within 36 countries. Methods: In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015, from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients, peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish region of Cantabria. For patients commencing RRT during 2006–10, the 5-year unadjusted patient survival probabilities on all RRT modalities combined was 50.0% (95% confidence interval 49.9–50.1).en_US
dc.languageEN
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleThe European Renal Association - European Dialysis and Transplantation Association (ERA-EDTA) registry Annual Report 2015: a summaryen_US
dc.typeJournal articleen_US
dc.creator.authorKramer, Anneke
dc.creator.authorPippias, Maria
dc.creator.authorNoordzij, Marlies
dc.creator.authorStel, VS
dc.creator.authorAfentakis, Nikolaos
dc.creator.authorAmbühl, Patrice M
dc.creator.authorAndrusev, AM
dc.creator.authorFuster, EA
dc.creator.authorMonzon, Federico E
dc.creator.authorÅsberg, Anders
dc.creator.authorBarbullushi, M
dc.creator.authorBonthius, Marjolein
dc.creator.authorCaskey, Fergus J
dc.creator.authorDe La Nuez, Pablo Castro
dc.creator.authorCernevskis, Harijs
dc.creator.authordes Grottes, Jean-Marin
dc.creator.authorGarneata, Liliana
dc.creator.authorGolan, Eliezer
dc.creator.authorHemmelder, Marc H.
dc.creator.authorIoannou, Kyriakos
dc.creator.authorJarraya, Facial
dc.creator.authorKolesnyk, Mykola
dc.creator.authorKomissarov, Kirill
dc.creator.authorLassalle, Mathilde
dc.creator.authorMacário, Fernando
dc.creator.authorMahillo-Duran, Beatriz
dc.creator.authorde Francisco, A
dc.creator.authorPálsson, Runólfur
dc.creator.authorPechter, Ülle
dc.creator.authorResic, Halima
dc.creator.authorRutkowski, Boleslaw
dc.creator.authorDe Pablos, Carmen Santiuste
dc.creator.authorSeyahi, Nurhan
dc.creator.authorOgrizovic, Sanja Simic
dc.creator.authorRoblero, María Fernanda Slon
dc.creator.authorSpustová, Viera
dc.creator.authorStojceva-Taneva, Olivera
dc.creator.authorTraynor, Jamie P.
dc.creator.authorMassy, Ziad A.
dc.creator.authorJager, Kitty J
cristin.unitcode185,15,23,0
cristin.unitnameFarmasøytisk institutt
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1562812
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical Kidney Journal&rft.volume=11&rft.spage=108&rft.date=2018
dc.identifier.jtitleClinical Kidney Journal
dc.identifier.volume11
dc.identifier.issue1
dc.identifier.startpage108
dc.identifier.endpage122
dc.identifier.doihttp://dx.doi.org/10.1093/ckj/sfx149
dc.identifier.urnURN:NBN:no-64323
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn2048-8505
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/61718/2/Kramer%2BCKJ2018.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International